The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...

Women who have rebound weight gain after stopping Wegovy or similar jabs end up gaining more weight during pregnancy, leading ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. | Vanda Pharmaceuticals’ ...

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 ...

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

The results show the treatment's potential to mitigate GLP-1 induced nausea and vomiting, which are key factors for those who stop using weight-loss drugs, Vanda Chief Executive Mihael Polymeropoulos ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

​Novo Nordisk A/S (NYSE: NVO) is one of the Most Profitable Stocks to Buy Now. On November 17, Reuters reported that Novo ...

Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite ...